1. Home
  2. KALV vs LGIH Comparison

KALV vs LGIH Comparison

Compare KALV & LGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.79

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo LGI Homes Inc.

LGIH

LGI Homes Inc.

HOLD

Current Price

$44.17

Market Cap

1.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
LGIH
Founded
N/A
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
KALV
LGIH
Price
$26.79
$44.17
Analyst Decision
Strong Buy
Hold
Analyst Count
5
5
Target Price
$32.60
$75.90
AVG Volume (30 Days)
5.4M
405.8K
Earning Date
07-09-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.09
Revenue
$50,000,000.00
$1,705,504,000.00
Revenue This Year
$185.42
$2.32
Revenue Next Year
$59.23
$17.94
P/E Ratio
N/A
$488.67
Revenue Growth
495.66
N/A
52 Week Low
$9.83
$33.55
52 Week High
$26.85
$69.42

Technical Indicators

Market Signals
Indicator
KALV
LGIH
Relative Strength Index (RSI) 74.85 51.58
Support Level $14.25 $41.82
Resistance Level $26.85 $49.51
Average True Range (ATR) 0.07 2.28
MACD -0.19 -0.45
Stochastic Oscillator 72.73 58.12

Price Performance

Historical Comparison
KALV
LGIH

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About LGIH LGI Homes Inc.

LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.

Share on Social Networks: